Form 4: Xeris Biopharma COO's Latest Stock Transactions

Xeris Biopharma's President and COO, Kevin McCulloch, reported routine stock transactions including shares withheld for taxes and an Employee Stock Purchase Plan acquisition.

Summary

• Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma Holdings, Inc., reported transactions involving the company's common stock.
• On August 1, 2025, 14,651 shares of common stock were disposed of at a price of $5.38 per share. These shares were withheld by Xeris Biopharma to cover income tax and withholding obligations related to the net settlement of vested restricted stock units.
• Following these transactions, Kevin McCulloch directly beneficially owns 1,701,159 shares of common stock.
• This direct ownership includes 7,225 shares purchased on June 30, 2025, through participation in the company's 2018 Employee Stock Purchase Plan.
• Additionally, 25,000 shares are indirectly owned by his spouse and 2,000 shares by the Charles R. McCulloch Trust dated 1990, though the reporting person disclaims beneficial ownership except for pecuniary interest.

Sentiment

Score: 6

Explanation: The filing is largely neutral as it details routine transactions (tax withholding for RSU vesting). The purchase of shares through an Employee Stock Purchase Plan adds a slight positive sentiment, indicating continued executive participation and investment in the company.

Positives

• Inclusion of 7,225 shares purchased through the 2018 Employee Stock Purchase Plan indicates ongoing participation and potential confidence in the company by a key executive.

Negatives

• The disposition of 14,651 shares, although for tax purposes, represents a reduction in direct beneficial ownership from the vested restricted stock units.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of an insider's stock transactions, common across all publicly traded industries, including biopharma. It reflects standard compensation practices involving restricted stock units and employee stock purchase plans.

Comparison to Industry Standards

• This type of transaction (shares withheld for tax on RSU vesting and ESPP purchases) is a standard and common practice for executives in publicly traded companies across various industries, including biopharma. It does not indicate any deviation from typical corporate compensation and tax compliance procedures.

Related Party Transactions

• The disposition of 14,651 shares for tax withholding purposes and the acquisition of 7,225 shares through the Employee Stock Purchase Plan are transactions between an insider (Kevin McCulloch) and the company (Xeris Biopharma Holdings, Inc.), which are considered related party transactions in the context of insider trading disclosures.

Stakeholder Impact

• Shareholders: Provides transparency regarding an executive's stock holdings and transactions, which can inform investment decisions. The net effect on total shares outstanding is minimal from this specific filing.
• Employees: The mention of the Employee Stock Purchase Plan highlights a benefit available to employees, potentially boosting morale and alignment.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, specifically shares withheld for tax obligations upon RSU vesting and a purchase through an Employee Stock Purchase Plan. These are standard occurrences and do not provide new fundamental information that would warrant a change in investment thesis. The ESPP purchase is a minor positive, but the overall activity is neutral, suggesting no immediate reason to alter a 'hold' position based solely on this disclosure.

Keywords

Xeris Biopharma, XERS, SEC Form 4, Insider Trading, Stock Transaction, Kevin McCulloch, Restricted Stock Units, Employee Stock Purchase Plan, Biopharma, Pharmaceuticals